Rhythm presents 2.5-year setmelanotide data in pediatric acquired hypothalamic obesity trial

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

RYTM

0.00
  • Rhythm Pharmaceuticals outlined new setmelanotide data in acquired hypothalamic obesity, with results already presented at Pediatric Endocrine Society annual meeting in San Francisco.
  • Longer-term follow-up in pediatric patients from earlier Phase 2 work showed sustained improvement in weight-related outcomes over 2.5 years, supporting durability of effect.
  • Separate Phase 3 TRANSCEND pediatric analyses presented showed more patients moved into lower weight categories at 1 year on setmelanotide versus placebo, with some reaching healthy weight or overweight classifications.
  • Safety findings were broadly consistent with setmelanotide’s established profile, with no new signals highlighted in these presentations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040800PRIMZONEFULLFEED9711377) on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.